XML 53 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue Recognition - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Other Revenues [Line Items]          
Revenue $ 178,216,000 $ 94,060,000 $ 484,013,000 $ 257,612,000  
Revenue Benchmark [Member]          
Other Revenues [Line Items]          
Revenue         $ 0
Revenue Benchmark [Member] | Customer Concentration Risk | Minimum [Member]          
Other Revenues [Line Items]          
Concentration Risk, Percentage         10.00%
Pfizer [Member] | Revenue Benchmark [Member]          
Other Revenues [Line Items]          
Revenue $ 19,100,000        
Pfizer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk          
Other Revenues [Line Items]          
Concentration Risk, Percentage 11.00%        
Pfizer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk | Minimum [Member]          
Other Revenues [Line Items]          
Concentration Risk, Percentage 10.00% 10.00%      
Millipore Sigma [Member] | Revenue Benchmark [Member]          
Other Revenues [Line Items]          
Revenue       $ 29,400,000  
Millipore Sigma [Member] | Revenue Benchmark [Member] | Customer Concentration Risk          
Other Revenues [Line Items]          
Concentration Risk, Percentage       11.00%  
Millipore Sigma [Member] | Revenue Benchmark [Member] | Customer Concentration Risk | Minimum [Member]          
Other Revenues [Line Items]          
Concentration Risk, Percentage     10.00% 10.00%